Tempus AI Imaging

What is Tempus Pixel and where does it come from?

Tempus AI, Inc. is based in Chicago and led by founder and CEO Eric Lefkofsky. It has traded on Nasdaq as TEM since June 14, 2024. Tempus acquired Arterys in 2022, and Arterys, Inc. is still the applicant name on the FDA records.

Tempus describes Pixel as an AI-powered cardiac imaging platform in a September 2025 press release. Its radiology page frames Pixel for radiology as a way to read images, detect findings and generate reports, and Pixel for oncology as a way to monitor disease progression.

What does it do, module by module?

Radiology covers automated lesion segmentation and measurement, longitudinal tracking and RECIST-style response reports. Oncology offers one-click lesion segmentation on CT and MR with editable reports. The cardiac module analyzes cardiac MR, and the 2025 update lets Pixel generate T1 and T2 inline maps from raw MRI data. Lung handles nodule detection, quantification and tracking on chest CT. Breast detects and tracks lesions on 2D and 3D images. Prostate does lesion detection and risk classification.

Tempus claims 100 or more health systems, over 2 billion images and more than 20 algorithms. It says Pixel integrates with existing PACS, EHR, worklist, notification and dictation systems.

Which parts are Tempus's own?

Not all of them. The page names five third-party engines: DeepLook Precise (K202084), InferRead CT from Infervision (K192880), iCAD ProFound AI (K203822), Quibim QP-Prostate (K203582) and QP-Prostate CAD (K242683). The breast, prostate and lung components use these partners.

A footnote on the page states that Pixel Lung is FDA cleared (K203744) but is not indicated for lung nodule detection, which in the US comes from a third-party engine. Nodule detection is CE marked in the EU.

What is FDA cleared?

The FDA lists eight 510(k)s under the applicant name Arterys, Inc., running from the Arterys Software v2.0 in October 2016 to Tempus Pixel (K252539) on September 3, 2025. The ones between them include Arterys Cardio DL (K163253, January 2017), Arterys Viewer (K171544, July 2017), Arterys Oncology DL (K173542, January 2018) and three Arterys MICA clearances, the latest K203744 in March 2022. Tempus also holds separate AI-ECG clearances, which belong to a different product line.

What studies does Tempus cite?

The vendor's footnotes cite studies about the underlying engines or an earlier research product, including Conant 2019 in Radiology: Artificial Intelligence on concurrent AI for digital breast tomosynthesis, Kozuka 2020 in the Japanese Journal of Radiology on lung CAD, and a 2019 JACC abstract by Narang on left ventricular volumes. They describe parts of the platform and not necessarily its current version.

How is Pixel sold?

Pixel is sold by enterprise quote, and the radiology page lists no price.

The verdict

Pixel is a suite of modules built on different engines, each with its own label. The cardiac MR and oncology measurement tools carry the Arterys lineage and the longest FDA history. A department that wants only breast, prostate or lung nodule detection is buying a partner's clearance through Tempus, and a buyer who wants one vendor's own algorithm across all organs will not find that here.